Dr. Lance Myers Joins HeartBeam as Chief AI Scientist

HeartBeam Inc. has appointed Lance Myers, Ph.D., chief artificial intelligence (AI) scientist. In this newly created position, Dr. Myers will help guide the ways in which AI is applied to the company’s core technology.
 
“We’ve made tremendous progress with our deep learning approach with data demonstrating that combining HeartBeam AI with a vector-based approach delivered equivalent performance to a 12-lead ECG and greatly improved detection of atrial flutter over a single-lead ECG,” HeartBeam Founder/CEO Branislav Vajdic, Ph.D., said. “As we enter the next phase of development, we’re pleased to have an industry leader of Lance’s caliber join our team. His insights and expertise will have an immediate impact as we strive to transform cardiac care by harnessing the power of AI with our data-rich technology.”

Most recently, Dr. Myers was an AI advisor to HeartBeam. Previously, he was the head of Cardiovascular Devices at Verily Life Sciences (formerly Google Life Sciences), where he led a team developing a novel heart failure monitoring solution. Prior to that, he worked as the head of Data Science at Verily and built a high-performance AI organization with teams in computational biology, medical device and biosensor algorithms, digital biomarkers, health informatics and digital pathology. He has also held leadership roles at XAI.health, Sentrian, VivoSense, Boston Neurosciences, and Vivometrics. He currently serves as a board member for VivoSense and is on the scientific advisory boards of Acorai, XAI.health, and Bryte.

Dr. Myers earned his Ph.D. in biomedical engineering from the University of Cape Town in South Africa.

“Being appointed as chief AI scientist is both an honor and an exciting challenge. The HeartBeam technology, when combined with advanced AI, has tremendous potential to unlock and deliver groundbreaking cardiac management solutions spanning diagnostics, screening, predictive analytics and closed-loop patient management—where detection, intervention and real-time measurement continually refine and optimize treatment outcomes,” Dr. Myers stated. “By leveraging longitudinal trends and increasing user data, we can uncover new insights, pushing the boundaries of AI in cardiac care and bringing transformative advancements to patients.” 
 
HeartBeam’s core technology captures the heart’s electrical signals from three dimensions to provide total heart intelligence. The company’s first application of the technology is a cable-free, credit card-sized device that is designed to be capable of synthesizing a 12-lead ECG. The HeartBeam system is currently under review with the U.S. Food and Drug Administration and is the foundational 510(k) submission upon which future submissions will be based. The company has 13 issued U.S. patents and four issued international patents supporting the underlying technology.
 
By leveraging AI to analyze the data-rich signals, the company believes it can improve diagnostic accuracy and unlock a more personalized approach to cardiac care for patients. As a patient uses the HeartBeam device over time, there will be a series of ECG readings. HeartBeam aims to leverage AI to analyze the data to provide a longitudinal view of the patient’s cardiac status and move beyond today’s 12-lead ECGs, which typically only provide a snapshot in time. HeartBeam AI is currently under development.
 
HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence.